Not a good buy right now for an impatient trader: the chart is in a clear bearish structure (SMA_200 > SMA_20 > SMA_5) and momentum is still deteriorating.
Today’s regular-session drop (-7.92%) with only a small post-market bounce (+2.27%) looks more like a weak relief move than a reversal.
Nearest support is S1 ~2.184 (price is sitting on it). If that breaks, the next downside area is S2 ~1.946; upside hurdles are heavy into Pivot ~2.57 and R1 ~2.956.
Momentum: MACD histogram is negative (-0.000734) and negatively expanding, implying bearish momentum is strengthening rather than stabilizing.
RSI: RSI_6 at 35.285 is near oversold but still “neutral” per provided label—this can support a bounce, but not a reliable trend reversal by itself.
Levels to watch: Support S1 2.184 (immediate), S2 1.946 (next). Resistance Pivot 2.57, then R1 2.956.
Pattern-based forward odds: ~60% chance of a slightly negative next day (-0.21%), but modestly positive bias over 1 week (+3.38%) / 1 month (+2.86%)—this is not strong enough to override the current downtrend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Reported put/call ratios are 0 (open interest and volume), which typically indicates limited/illiquid options activity or insufficient reporting—sentiment read-through is low-confidence.
Historical volatility is extremely high (151.33), consistent with speculative, high-risk price swings; options (where tradable) are likely pricing large moves.
Technical Summary
Sell
9
Buy
3
Positive Catalysts
holds, given RSI is getting stretched.
Neutral/Negative Catalysts
increases the likelihood of sharp downside continuations.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 0 (no meaningful operating revenue; YoY change listed as 0.00%).
Net income: -3,799,240 (loss widened by ~11.97% YoY).
EPS: -5 (deteriorated ~-91.89% YoY as provided).
Overall: financial trend shows ongoing losses with no revenue traction in the snapshot—doesn’t support a near-term “buy now” thesis for an impatient entry.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating / price target change data was provided, so a recent trend summary cannot be validated from this dataset.
Wall Street-style pros (general): biotech optionality if pipeline catalysts emerge; upside can be large on positive clinical/regulatory updates.
Wall Street-style cons (general): lack of revenue, ongoing losses, and high volatility make timing-dependent trades difficult; absent a clear catalyst, downside risk tends to dominate.
Influential/Political trading check: No recent congress trading data available; hedge funds and insiders are reported as Neutral with no significant recent trends.
Wall Street analysts forecast GNPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNPX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast GNPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNPX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
